Free Trial

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 3.2%

Arrowhead Pharmaceuticals logo with Medical background

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) shares shot up 3.2% during mid-day trading on Friday . The stock traded as high as $24.71 and last traded at $24.54. 20,985 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,312,528 shares. The stock had previously closed at $23.79.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ARWR. Morgan Stanley reduced their price target on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an "equal weight" rating for the company in a research report on Monday, May 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, June 3rd. HC Wainwright reaffirmed a "buy" rating and set a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 11th. Finally, The Goldman Sachs Group began coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They set a "neutral" rating and a $31.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $47.89.

View Our Latest Report on ARWR

Arrowhead Pharmaceuticals Trading Up 7.2 %

The business has a 50 day moving average of $24.07 and a two-hundred day moving average of $28.25. The firm has a market cap of $3.17 billion, a P/E ratio of -5.92 and a beta of 0.94.


Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same period in the prior year, the firm posted $0.45 earnings per share. The company's quarterly revenue was down 100.0% on a year-over-year basis. On average, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.05 EPS for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of the company's stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the transaction, the director now directly owns 30,205 shares of the company's stock, valued at approximately $704,078.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Avoro Capital Advisors LLC grew its holdings in Arrowhead Pharmaceuticals by 657.1% in the 1st quarter. Avoro Capital Advisors LLC now owns 8,555,555 shares of the biotechnology company's stock valued at $244,689,000 after buying an additional 7,425,555 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 16.2% during the 1st quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company's stock worth $354,756,000 after purchasing an additional 1,731,974 shares in the last quarter. FMR LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 58.2% during the 3rd quarter. FMR LLC now owns 4,308,903 shares of the biotechnology company's stock worth $115,780,000 after purchasing an additional 1,584,425 shares in the last quarter. Norges Bank acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $40,451,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 136.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,061,967 shares of the biotechnology company's stock worth $32,496,000 after purchasing an additional 613,067 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Featured Stories

→ New Biden Law just went into effect (From Stansberry Research) (Ad)

Should you invest $1,000 in Arrowhead Pharmaceuticals right now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines